Phenotype, dystrophin prediction, variant classification and longitudinal function all matter. A VUS is not automatically diagnostic; request expert reinterpretation or a second genetics opinion when the report and symptoms conflict.
What this means in real life
Duchenne and Becker are both dystrophinopathies caused by DMD-gene variants. Becker usually allows more dystrophin function and has a later or milder course, but the boundary is not defined by a single age or symptom. The predicted reading frame is useful, yet exceptions mean the team must consider the exact variant, clinical pattern, laboratory classification and change over time.
A variant of uncertain significance, or VUS, means available evidence is not sufficient to label the variant disease-causing or benign. A VUS should not be treated as automatically diagnostic or used alone for mutation-specific treatment. Helpful next steps can include parental testing, expert laboratory reanalysis, checking whether the phenotype matches, reviewing population and disease databases and, in selected cases, RNA or dystrophin studies.
Seek a second opinion when the report language and the child’s presentation do not align, when the result is uncertain, or when a major irreversible treatment depends on the interpretation. Ask both the laboratory and clinic to update the family if the classification changes.
A practical checklist
- ✓
Read the report’s classification—not only the gene and exon numbers.
- ✓
Compare clinical features and trajectory with the predicted variant effect.
- ✓
Request expert reanalysis and parental studies for a VUS.
- ✓
Do not use a VUS alone to claim treatment eligibility.
- ✓
Arrange a second genetics/neuromuscular review before irreversible decisions.
Questions to bring with you
Use these at the clinic, school meeting, equipment evaluation, program interview or benefits call. Write down the answers and who owns the next step.
- What evidence supports Duchenne versus Becker in this case?
- What evidence keeps this variant uncertain?
- Could family testing or RNA/protein testing change classification?
- How often will the laboratory re-evaluate the variant?
- Would the diagnostic uncertainty change care now?
Important context
Individual needs, eligibility and safety can differ. Confirm the plan with the relevant Duchenne-experienced clinician, therapist, school team or program before acting.
Sources used for this guide
Direct links are included so families can check the original guidance and bring it to qualified professionals.
Content review: July 18, 2026. Medical labels, trials, benefits and programs can change after publication.
Did this article answer the question?
A thumbs-down sends the article to the private administrator dashboard for review.